[go: up one dir, main page]

MX2018007704A - Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. - Google Patents

Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.

Info

Publication number
MX2018007704A
MX2018007704A MX2018007704A MX2018007704A MX2018007704A MX 2018007704 A MX2018007704 A MX 2018007704A MX 2018007704 A MX2018007704 A MX 2018007704A MX 2018007704 A MX2018007704 A MX 2018007704A MX 2018007704 A MX2018007704 A MX 2018007704A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
antioxidant
amorphous lenalidomide
treatment
pharmaceutically acceptable
Prior art date
Application number
MX2018007704A
Other languages
English (en)
Other versions
MX385876B (es
Inventor
Vivancos Martinez Marta
Alvarez Fernandez Lisardo
Velada Calzada Jose
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of MX2018007704A publication Critical patent/MX2018007704A/es
Publication of MX385876B publication Critical patent/MX385876B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende lenalidomida amorfa, o una sal farmacéuticamente aceptable de la misma, con un antioxidante sintético y uno o más excipientes farmacéuticamente aceptables; la invención se refiere además al procedimiento para fabricar tales composiciones y al uso de dicha composición como un medicamento, particularmente en el tratamiento del mieloma múltiple y síndromes mielodisplásicos.
MX2018007704A 2015-12-22 2016-12-22 Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. MX385876B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15202069 2015-12-22
PCT/EP2016/082318 WO2017109041A1 (en) 2015-12-22 2016-12-22 Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant

Publications (2)

Publication Number Publication Date
MX2018007704A true MX2018007704A (es) 2018-11-09
MX385876B MX385876B (es) 2025-03-18

Family

ID=55068830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007704A MX385876B (es) 2015-12-22 2016-12-22 Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.

Country Status (7)

Country Link
US (2) US10328028B2 (es)
EP (1) EP3393457A1 (es)
AU (1) AU2016378482A1 (es)
CL (1) CL2018001705A1 (es)
EA (1) EA036205B1 (es)
MX (1) MX385876B (es)
WO (1) WO2017109041A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10507204B2 (en) * 2014-12-19 2019-12-17 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
ES2927984T3 (es) 2016-06-20 2022-11-14 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018013693A1 (en) * 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
ES2929193T3 (es) 2016-12-22 2022-11-25 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
RU2020110236A (ru) 2017-10-26 2021-11-26 Синбиас Фарма АГ Состав леналидомида с немедленным высвобождением
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
WO2019199136A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 붕해가 개선된 레날리도마이드의 경구용 정제 조성물
PL3790877T3 (pl) 2018-05-11 2023-06-12 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
MX2021012901A (es) * 2019-04-22 2021-11-17 Starton Therapeutics Inc Metodo de administracion continua de lenalidomida y otros agentes inmunomoduladores.
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
CN114829366A (zh) 2019-11-11 2022-07-29 因赛特公司 Pd-1/pd-l1抑制剂的盐及结晶形式
CN110664761A (zh) * 2019-11-18 2020-01-10 杭州百诚医药科技股份有限公司 一种来那度胺药物组合物及其制备方法
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
EP4251131A1 (en) 2021-01-08 2023-10-04 Starton Therapeutics, Inc. Stable solutions of immunomodulatory imide compounds for parenteral use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739802D1 (de) 1996-07-24 2010-04-22 Celgene Corp Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
KR20100124710A (ko) 2008-03-11 2010-11-29 닥터 레디스 레보러터리즈 리미티드 레날리도미드의 제조
JP2012507496A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド レナリドマイドの結晶形およびその調製方法
EP2355802A1 (de) * 2008-11-14 2011-08-17 Ratiopharm GmbH Intermediate und orale darreichungsformen enthaltend lenalidomid
US8946265B2 (en) * 2009-03-02 2015-02-03 Generics [Uk] Limited Process for the preparation of lenalidomide
CN101537184B (zh) * 2009-04-30 2011-04-20 杭州中美华东制药有限公司 一种含水难溶高活性药物的组合物及其制备方法
CA2793312C (en) 2010-03-08 2016-06-14 Natco Pharma Limited Anhydrous lenalidomide form-i
US20150126582A1 (en) * 2012-04-30 2015-05-07 Sevion Therapeutics, Inc. Combination Treatment of Multiple Myeloma
US9808450B2 (en) * 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103705485B (zh) * 2013-12-31 2015-07-22 广州帝奇医药技术有限公司 一种用于治疗骨髓增生异常综合症的组合物及其制备方法

Also Published As

Publication number Publication date
AU2016378482A1 (en) 2018-07-12
US20190240157A1 (en) 2019-08-08
EA036205B1 (ru) 2020-10-14
MX385876B (es) 2025-03-18
US10328028B2 (en) 2019-06-25
US11007152B2 (en) 2021-05-18
US20180256501A1 (en) 2018-09-13
CL2018001705A1 (es) 2018-08-10
WO2017109041A1 (en) 2017-06-29
EP3393457A1 (en) 2018-10-31
EA201891489A1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2018006223A (es) Moduladores de ror-gamma.
WO2016011306A3 (en) Terminal modifications of polynucleotides
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
WO2016040952A3 (en) BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12018500358A1 (en) Compounds for use in an antibacterial applications
EP3288636A4 (en) COMPOSITIONS FOR THE TREATMENT OF EPISTAXIS
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2015001541A3 (en) Pharmaceutical film composition
IN2014MU00916A (es)
PH12016501997B1 (en) Cycloalkyl-linked diheterocycle derivatives
IN2013MU01985A (es)
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
PH12020500045A1 (en) Novel composition of enzalutamide oral dosage form and method of manufacturing thereof
MX2018005134A (es) Formulacion de factor viii (fviii).
IN2013MU03428A (es)